234 related articles for article (PubMed ID: 21116692)
1. Temozolomide-based dry powder formulations for lung tumor-related inhalation treatment.
Wauthoz N; Deleuze P; Saumet A; Duret C; Kiss R; Amighi K
Pharm Res; 2011 Apr; 28(4):762-75. PubMed ID: 21116692
[TBL] [Abstract][Full Text] [Related]
2. New dry powders for inhalation containing temozolomide-based nanomicelles for improved lung cancer therapy.
Rosière R; Gelbcke M; Mathieu V; Van Antwerpen P; Amighi K; Wauthoz N
Int J Oncol; 2015 Sep; 47(3):1131-42. PubMed ID: 26201404
[TBL] [Abstract][Full Text] [Related]
3. L-Leucine as an excipient against moisture on in vitro aerosolization performances of highly hygroscopic spray-dried powders.
Li L; Sun S; Parumasivam T; Denman JA; Gengenbach T; Tang P; Mao S; Chan HK
Eur J Pharm Biopharm; 2016 May; 102():132-41. PubMed ID: 26970252
[TBL] [Abstract][Full Text] [Related]
4. Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride.
Karimi K; Katona G; Csóka I; Ambrus R
J Pharm Biomed Anal; 2018 Jan; 148():73-79. PubMed ID: 28965047
[TBL] [Abstract][Full Text] [Related]
5. Spray-dried carrier-free dry powder tobramycin formulations with improved dispersion properties.
Pilcer G; Vanderbist F; Amighi K
J Pharm Sci; 2009 Apr; 98(4):1463-75. PubMed ID: 18752304
[TBL] [Abstract][Full Text] [Related]
6. Development of a microparticle-based dry powder inhalation formulation of ciprofloxacin hydrochloride applying the quality by design approach.
Karimi K; Pallagi E; Szabó-Révész P; Csóka I; Ambrus R
Drug Des Devel Ther; 2016; 10():3331-3343. PubMed ID: 27784991
[TBL] [Abstract][Full Text] [Related]
7. Design and physicochemical characterization of advanced spray-dried tacrolimus multifunctional particles for inhalation.
Wu X; Hayes D; Zwischenberger JB; Kuhn RJ; Mansour HM
Drug Des Devel Ther; 2013; 7():59-72. PubMed ID: 23403805
[TBL] [Abstract][Full Text] [Related]
8. Protection of hydrophobic amino acids against moisture-induced deterioration in the aerosolization performance of highly hygroscopic spray-dried powders.
Yu J; Chan HK; Gengenbach T; Denman JA
Eur J Pharm Biopharm; 2017 Oct; 119():224-234. PubMed ID: 28655664
[TBL] [Abstract][Full Text] [Related]
9. Development of a Carrier Free Dry Powder Inhalation Formulation of Ketotifen for Pulmonary Drug Delivery.
Azari F; Ghanbarzadeh S; Safdari R; Yaqoubi S; Adibkia K; Hamishehkar H
Drug Res (Stuttg); 2020 Jan; 70(1):26-32. PubMed ID: 31533157
[TBL] [Abstract][Full Text] [Related]
10. Development of controlled-release cisplatin dry powders for inhalation against lung cancers.
Levet V; Rosière R; Merlos R; Fusaro L; Berger G; Amighi K; Wauthoz N
Int J Pharm; 2016 Dec; 515(1-2):209-220. PubMed ID: 27737810
[TBL] [Abstract][Full Text] [Related]
11. Development of a novel dry powder inhalation formulation for the delivery of rivastigmine hydrogen tartrate.
Simon A; Amaro MI; Cabral LM; Healy AM; de Sousa VP
Int J Pharm; 2016 Mar; 501(1-2):124-38. PubMed ID: 26836711
[TBL] [Abstract][Full Text] [Related]
12. New respirable and fast dissolving itraconazole dry powder composition for the treatment of invasive pulmonary aspergillosis.
Duret C; Wauthoz N; Sebti T; Vanderbist F; Amighi K
Pharm Res; 2012 Oct; 29(10):2845-59. PubMed ID: 22644590
[TBL] [Abstract][Full Text] [Related]
13. High-performing dry powder inhalers of paclitaxel DPPC/DPPG lung surfactant-mimic multifunctional particles in lung cancer: physicochemical characterization, in vitro aerosol dispersion, and cellular studies.
Meenach SA; Anderson KW; Hilt JZ; McGarry RC; Mansour HM
AAPS PharmSciTech; 2014 Dec; 15(6):1574-87. PubMed ID: 25139763
[TBL] [Abstract][Full Text] [Related]
14. Puerarin dry powder inhaler formulations for pulmonary delivery: Development and characterization.
Rashid MA; Muneer S; Wang T; Alhamhoom Y; Rintoul L; Izake EL; Islam N
PLoS One; 2021; 16(4):e0249683. PubMed ID: 33848310
[TBL] [Abstract][Full Text] [Related]
15. Heat-Stable Dry Powder Oxytocin Formulations for Delivery by Oral Inhalation.
Fabio K; Curley K; Guarneri J; Adamo B; Laurenzi B; Grant M; Offord R; Kraft K; Leone-Bay A
AAPS PharmSciTech; 2015 Dec; 16(6):1299-306. PubMed ID: 25776985
[TBL] [Abstract][Full Text] [Related]
16. Overcoming dose limitations using the orbital(®) multi-breath dry powder inhaler.
Young PM; Crapper J; Philips G; Sharma K; Chan HK; Traini D
J Aerosol Med Pulm Drug Deliv; 2014 Apr; 27(2):138-47. PubMed ID: 24004178
[TBL] [Abstract][Full Text] [Related]
17. The role of fines in the modification of the fluidization and dispersion mechanism within dry powder inhaler formulations.
Shur J; Harris H; Jones MD; Kaerger JS; Price R
Pharm Res; 2008 Jul; 25(7):1631-40. PubMed ID: 18239861
[TBL] [Abstract][Full Text] [Related]
18. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
Le VN; Robins E; Flament MP
Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
[TBL] [Abstract][Full Text] [Related]
19. Novel dry powder inhalation system based on dispersion of lyophilisates.
Claus S; Schoenbrodt T; Weiler C; Friess W
Eur J Pharm Sci; 2011 May; 43(1-2):32-40. PubMed ID: 21440061
[TBL] [Abstract][Full Text] [Related]
20. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
